Anne M Pesenacker1, Virginia Chen2, Jana Gillies1, Cate Speake3, Ashish K Marwaha4, Annika Sun1, Samuel Chow5, Rusung Tan6, Thomas Elliott7, Jan P Dutz5, Scott J Tebbutt2, Megan K Levings1. 1. Department of Surgery, University of British Columbia (UBC), and BC Children's Hospital Research Institute (BCCHRI), Vancouver, British Columbia, Canada. 2. Department of Medicine and Centre for Heart Lung Innovation, UBC, and Prevention of Organ Failure (PROOF) Centre of Excellence, St. Paul's Hospital, Vancouver, British Columbia, Canada. 3. Diabetes Clinical Research Program, Benaroya Research Institute, Seattle, Washington, USA. 4. Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada. 5. Department of Dermatology, UBC, and BCCHRI, Vancouver, British Columbia, Canada. 6. Department of Pathology, Sidra Medicine, Weill Cornell Medicine, Doha, Qatar. 7. Department of Medicine, UBC, and BCDiabetes, Vancouver, British Columbia, Canada.
Abstract
BACKGROUND: Multiple therapeutic strategies to restore immune regulation and slow type 1 diabetes (T1D) progression are in development and testing. A major challenge has been defining biomarkers to prospectively identify subjects likely to benefit from immunotherapy and/or measure intervention effects. We previously found that, compared with healthy controls, Tregs from children with new-onset T1D have an altered Treg gene signature (TGS), suggesting that this could be an immunoregulatory biomarker. METHODS: nanoString was used to assess the TGS in sorted Tregs (CD4+CD25hiCD127lo) or peripheral blood mononuclear cells (PBMCs) from individuals with T1D or type 2 diabetes, healthy controls, or T1D recipients of immunotherapy. Biomarker discovery pipelines were developed and applied to various sample group comparisons. RESULTS: Compared with controls, the TGS in isolated Tregs or PBMCs was altered in adult new-onset and cross-sectional T1D cohorts, with sensitivity or specificity of biomarkers increased by including T1D-associated SNPs in algorithms. The TGS was distinct in T1D versus type 2 diabetes, indicating disease-specific alterations. TGS measurement at the time of T1D onset revealed an algorithm that accurately predicted future rapid versus slow C-peptide decline, as determined by longitudinal analysis of placebo arms of START and T1DAL trials. The same algorithm stratified participants in a phase I/II clinical trial of ustekinumab (αIL-12/23p40) for future rapid versus slow C-peptide decline. CONCLUSION: These data suggest that biomarkers based on measuring TGSs could be a new approach to stratify patients and monitor autoimmune activity in T1D. FUNDING: JDRF (1-PNF-2015-113-Q-R, 2-PAR-2015-123-Q-R, 3-SRA-2016-209-Q-R, 3-PDF-2014-217-A-N), the JDRF Canadian Clinical Trials Network, the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (UM1AI109565 and FY15ITN168), and BCCHRI.
BACKGROUND: Multiple therapeutic strategies to restore immune regulation and slow type 1 diabetes (T1D) progression are in development and testing. A major challenge has been defining biomarkers to prospectively identify subjects likely to benefit from immunotherapy and/or measure intervention effects. We previously found that, compared with healthy controls, Tregs from children with new-onset T1D have an altered Treg gene signature (TGS), suggesting that this could be an immunoregulatory biomarker. METHODS: nanoString was used to assess the TGS in sorted Tregs (CD4+CD25hiCD127lo) or peripheral blood mononuclear cells (PBMCs) from individuals with T1D or type 2 diabetes, healthy controls, or T1D recipients of immunotherapy. Biomarker discovery pipelines were developed and applied to various sample group comparisons. RESULTS: Compared with controls, the TGS in isolated Tregs or PBMCs was altered in adult new-onset and cross-sectional T1D cohorts, with sensitivity or specificity of biomarkers increased by including T1D-associated SNPs in algorithms. The TGS was distinct in T1D versus type 2 diabetes, indicating disease-specific alterations. TGS measurement at the time of T1D onset revealed an algorithm that accurately predicted future rapid versus slow C-peptide decline, as determined by longitudinal analysis of placebo arms of START and T1DAL trials. The same algorithm stratified participants in a phase I/II clinical trial of ustekinumab (αIL-12/23p40) for future rapid versus slow C-peptide decline. CONCLUSION: These data suggest that biomarkers based on measuring TGSs could be a new approach to stratify patients and monitor autoimmune activity in T1D. FUNDING: JDRF (1-PNF-2015-113-Q-R, 2-PAR-2015-123-Q-R, 3-SRA-2016-209-Q-R, 3-PDF-2014-217-A-N), the JDRF Canadian Clinical Trials Network, the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (UM1AI109565 and FY15ITN168), and BCCHRI.
Authors: Mark R Rigby; Linda A DiMeglio; Marc S Rendell; Eric I Felner; Jean M Dostou; Stephen E Gitelman; Chetanbabu M Patel; Kurt J Griffin; Eva Tsalikian; Peter A Gottlieb; Carla J Greenbaum; Nicole A Sherry; Wayne V Moore; Roshanak Monzavi; Steven M Willi; Philip Raskin; Antoinette Moran; William E Russell; Ashley Pinckney; Lynette Keyes-Elstein; Michael Howell; Sudeepta Aggarwal; Noha Lim; Deborah Phippard; Gerald T Nepom; James McNamara; Mario R Ehlers Journal: Lancet Diabetes Endocrinol Date: 2013-09-23 Impact factor: 32.069
Authors: Michael Elliott; Jacqueline Benson; Marion Blank; Carrie Brodmerkel; Daniel Baker; Kristin Ruley Sharples; Philippe Szapary Journal: Ann N Y Acad Sci Date: 2009-12 Impact factor: 5.691
Authors: Jeffrey A Bluestone; Jane H Buckner; Mark Fitch; Stephen E Gitelman; Shipra Gupta; Marc K Hellerstein; Kevan C Herold; Angela Lares; Michael R Lee; Kelvin Li; Weihong Liu; S Alice Long; Lisa M Masiello; Vinh Nguyen; Amy L Putnam; Mary Rieck; Peter H Sayre; Qizhi Tang Journal: Sci Transl Med Date: 2015-11-25 Impact factor: 17.956
Authors: Carla J Greenbaum; Craig A Beam; David Boulware; Stephen E Gitelman; Peter A Gottlieb; Kevan C Herold; John M Lachin; Paula McGee; Jerry P Palmer; Mark D Pescovitz; Heidi Krause-Steinrauf; Jay S Skyler; Jay M Sosenko Journal: Diabetes Date: 2012-06-11 Impact factor: 9.337
Authors: Stephen E Gitelman; Peter A Gottlieb; Eric I Felner; Steven M Willi; Lynda K Fisher; Antoinette Moran; Michael Gottschalk; Wayne V Moore; Ashley Pinckney; Lynette Keyes-Elstein; Kristina M Harris; Sai Kanaparthi; Deborah Phippard; Linna Ding; Jeffrey A Bluestone; Mario R Ehlers Journal: Diabetologia Date: 2016-04-06 Impact factor: 10.122
Authors: Simi Ahmed; Karen Cerosaletti; Eddie James; S Alice Long; Stuart Mannering; Cate Speake; Maki Nakayama; Timothy Tree; Bart O Roep; Kevan C Herold; Todd M Brusko Journal: Diabetes Date: 2019-07 Impact factor: 9.461
Authors: Cate Speake; Samuel O Skinner; Dror Berel; Elizabeth Whalen; Matthew J Dufort; William Chad Young; Jared M Odegard; Anne M Pesenacker; Frans K Gorus; Eddie A James; Megan K Levings; Peter S Linsley; Eitan M Akirav; Alberto Pugliese; Martin J Hessner; Gerald T Nepom; Raphael Gottardo; S Alice Long Journal: JCI Insight Date: 2019-12-05
Authors: Paul Minh Huy Tran; Lynn Kim Hoang Tran; Khaled Bin Satter; Sharad Purohit; John Nechtman; Diane I Hopkins; Bruno Dos Santos; Roni Bollag; Ravindra Kolhe; Suash Sharma; Jin Xiong She Journal: Cancers (Basel) Date: 2021-01-25 Impact factor: 6.639
Authors: Ashish K Marwaha; Samuel Chow; Anne M Pesenacker; Laura Cook; Annika Sun; S Alice Long; Jennie H M Yang; Kirsten A Ward-Hartstonge; Evangelia Williams; Clara Domingo-Vila; Khalif Halani; Kristina M Harris; Timothy I M Tree; Megan K Levings; Thomas Elliott; Rusung Tan; Jan P Dutz Journal: Immunother Adv Date: 2021-11-13
Authors: Joanne Boldison; Anna E Long; Rachel J Aitken; Isabel V Wilson; Clare Megson; Stephanie J Hanna; F Susan Wong; Kathleen M Gillespie Journal: Diabetologia Date: 2021-10-28 Impact factor: 10.122